17Sept. 2025
11.10 am-1.30 pm - OpeningWelcome and introduction: Eric Deutsch, phD, MD
Director of Gustave Roussy Radiation Oncology Department and INSERM UMR 1030
11.15 am-12.00 am – Keynote lecture - How to improve immunotherapy radiotherapy combinations
Pr Ralph Weichselbaum, Chicago University, USA12:00 pm-1:00 pm industrial session
Johnson & Johnson
Unlocking Novel Intratumoral Cancer Therapies Through Pharma and Medtech Synergies.1:00 pm-2:00 pm Coffee break and exhibition
11.10 am-1.30 pm: OPENINGWelcome and introduction
PRIMER ON RADIATIONS, CANCER IMMUNOLOGY AND IMMUNOTHERAPY
2.00 pm-4.00 pm Session I:Cancer immunology and Immunotherapy
(Oliver Kepp, Alexandre Bobard)
2:00 pm-2:30 pm: Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
Pr Tim Illidge
Manchester Cancer Research Center, UK 2:30 pm-3:00 pm: Diagnosis of gut dysbiosis and relevance for clinical outcome
Dr Lisa Derosa
Gustave Roussy, FR 3:00 pm-3:30 pm: Neuroendocrine control of tumor immunosurveillance
Pr Guido Kroemer
Cordeliers Research Center, FR 3:30 pm-4:00 pm: Impact of the mitochondrial hub on the cytotoxicity and immunogenicity of radiation therapy
Dr Lorenzo Galluzzi
Fox Chase Cancer Center, USA
4:00 pm-4:30 pm: Coffee break and exhibition 4.30 pm-6.30 pm Session II:Radiation dose, modalities and resistance
(François de Kermengy, Eric Deutsch)
4:30 pm-5:00 pm: Radiotherapy and immunotherapy: better with particles?
Pr Marco Durante
German Cancer Research Center, G 5:00 pm-5:30 pm: Heterogeneous intratumor irradiation: a new partner for immunotherapy
Dr Michele Mondini
Gustave Roussy, FR 5:30 pm-6:00 pm: Precision TIME reprogramming by next-generation particle radiotherapy
Pr Amir Abdollahi
NCT Heidelberg, G 6:00 pm-6:30 pm: Metabolic mechanisms of immune resistance in irradiated glioblastomas
Dr Claire Vanpouille-Box
Weill Cornell Medicine, USA
6.30 pm-9.00 pmCocktail poster session and exhibition
18Sept. 2025
MAIN PROGRAM
8.30-10.00 Session III:Myeloid cells
(Paul Bergeron, Jessica Zucman-Rossi)
8.30-9.00: Complementary roles of spatially restricted and ontogenically distinct lung macrophages during sepsis-trained immunity
Pr Antoine Roquilly
Nantes University, FR 9.00-9.30: Blocking IL-18BP improves tumour control by radiotherapy
Anne-Gaëlle Goubet
University of Geneva, Switzerland 9.30-10.00: Association of immunotherapy and radiotherapy in head and neck squamous cell carcinoma
Dr Yungan Tao
Gustave Roussy, FR 10.00-10.30 Coffee break and exhibition 10.30-12.30 Session IV:Immunosuppression
(Michele Mondini)
10.30-11.00: Unraveling the Complexity of Cancer Ecosystems Following Therapeutic Intervention
Pr Johanna Joyce
University of Lausanne, SW 11.00-11.30: Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
Dr Fatima Mechta-Grigoriou
Institut Curie, FR 11.30-12.00: Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1
Dr Monica Olcina
University of Oxford, UK 12.00-12.30: Microbiota-Primed Fibroblasts Contribute to Radiotherapy-Induced Lung Metastasis Progression
Dr András PIFFKÓ
University of Chicago, USA
12.30-14.00 Lunch break and exhibition13.00-14.00 – Telix industrial session
Radioligand therapies and immunomodulators: single riders or winning duo? 14.00-16.00 Session V:DNA damage
(Marco Moreira/Caroline Robert)
14.00-14.30: Deciphering the dialogue between irradiated cancer cells and dendritic cells to improve anti-tumor immune responses
Pr Sandra Demaria
Weill Cornell Medicine, USA14.30-15.00: Epigenetic, transcriptomic and genetic analyses of HR+/HER2- primary and metastatic breast cancer reveals heterogeneous mechanisms of endocrine therapy resistance
Dr Sergey Nikolaev
Gustave Roussy, FR 15.00-15.30: STING agonism during adjuvant immunotherapy for radiocurable cancers
Pr Kevin Harrington
ICR, UK 15.30-16.00: Radiation and replication stress induced sources of cytosolic nucleic acids and cGAS-STING activation
Dr Crispin Hiley
UCL Cancer Institute 16.00-16.30 coffee break and exhibition 16.30-18.00 Session VI:Next generation Immunotherapy
(Marie Morfouace, Laurie Menger)
16.30-17.00: Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Dr Jerome Galon
Cordeliers Research Center, FR17.00-17.30: Neutrophil extracellular traps in radioimmunotherapy
Pr Ignacio Melero
Clinica Universidad de Navarra, S 17.30-18.00: New immune-based approaches in the clinic
Pr Fabrice Barlesi
Gustave Roussy, FR 18.00-18.30: NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Dr Janna Heide
University of Chicago, USA
20.00-00.00Gala dinner
19Sept. 2025
8.30-10.0 Session VII:Tumor Microenvironment
(Marine Fidelle, Carolina Alves Costa Silva)
8.30-9.00: Biomarker-Guided Selection for FLASH and Low-Dose Immunomodulation,
Dr Fernanda Herrera
CHUV, SW 9.00-9.30: Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease
Pr Martin Pruschy
University Hospital Zurich 9.30-10.00: Tumour-immune microenvironment delineates the evolutionary trajectories of distinct phenotypes of locoregionally-advanced EBV-positive nasopharyngeal carcinoma
Dr Melvin Chua Lee Kiang
Duke-NUS Medical School, SG 10.00-10.30 Coffee break and exhibition 10.30-12.30 Session VIII:AI, Imaging and Radiomics
(Ibrahim Bouakka, Nathan Benzazon)
10.30-11.00: The use of PET for assessing on-treatment changes in radiolabeled anti-PD-L1 uptake during hemoradiotherapy in NSCLC
Pr Idris Bahce
Vanderbilt University Medical Center , NL 11.00-11.30: Translational frontiers and clinical opportunities of immunologically-fitted radiotherapy
Pr Eric Deutsch
Gustave Roussy, FR 11.30-12.00: Interventional Radiology For Cancer Immunotherapy: past, present and future
Pr Lambros Tselikas
Gustave Roussy, FR 12.00-12.30: Preserving the immune system in radiotherapy: modelling and AI tools
Dr Charlotte Robert
Gustave Roussy, FR 12.30-14.00 Lunch break and exhibition13.15-14.00 – Ankyra industrial session
Anchored Immunotherapy: Is there a role for the radiation oncologist? 14.00-16.00 Session IX:Adaptive Immunity
(Pierre-Antoine Laurent, Céline Mirjolet)
14.00-14.30: Emerging evidence for adapting radiotherapy to immunotherapy
Pr Silvia Formenti
Weill Cornell Medicine, USA 14.30-15.00: Immunoradiotherapy in solid tumors: Enhancing antitumor immunity through BO-112 and radiation-induced FAP modulation.
Dr Maria Esperanza Rodriguez Ruiz
Clinica Universidad de Navarra, S 15.00-15.30: Metabolism at the cross road between gut commensalism and cancer immunosurveillance
Pr Laurence Zitvogel
Gustave Roussy, FR 15.30-16.00: Targeting Mechanism of checkpoint resistance
Pr James Welsh
MD Anderson Cancer Center, USA 16.00-16.30 Coffee break and exhibition 16.30-18.00 Session X:Therapeutic Nuclear Medicine
(Lydia Meziani, Jean-Pierre Pouget)
16.30-17.00: Nuclear Medicine at the era of AI and Precision Oncology
Dr Desirée Deandreis
Gustave Roussy, FR 17.00-17.30: Radiolabeled antibody therapy in immunotherapy-resistant lung cancer: predicting outcomes via CD8 T lymphocyte immunoPET imaging
Dr Charles Truillet
CEA, FR 17.30-18.00: PD-1 blockade enhances therapeutic effects of anti-CEA 177Lu-DOTA-M5A in colorectal cancer CEA-transgenic mice
Dr Tabassom Mohajershojai
Karolinska Institute, STBD
About Us
Since 2016, Weill Cornell Medicine (New York) and the Gustave Roussy Cancer Campus (Paris) have joined forces to organize an annual conference that provides a forum for education, discussion, and networking among investigators interested in developing safe and effective RT-IT combinations (ImmunoRad).
Contact Info
Email
Tina Zaarour
Phone
+33 1 42 11 49 02
Gustave Roussy Cancer Campus,
Research Department
Pièce 65 - B2M
© Immunorad 2025, By ced-web
